Antibody-secreting macrophages generated using CpG-free plasmid eliminate tumor cells through antibody-dependent cellular phagocytosis |
Cha, Eun Bi
(Environmental Disease Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB))
Shin, Keun Koo (Environmental Disease Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB)) Seo, Jinho (Environmental Disease Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB)) Oh, Doo-Byoung (Environmental Disease Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB)) |
1 | Latz E, Schoenemeyer A, Visintin A et al (2004) TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol 5, 190-198 DOI |
2 | Hyde SC, Pringle IA, Abdullah S et al (2008) CpG-free plasmids confer reduced inflammation and sustained pulmonary gene expression. Nat Biotechnol 26, 549-551 DOI |
3 | Lesina E, Dames P, Flemmer A et al (2010) CpG-free plasmid DNA prevents deterioration of pulmonary function in mice. Eur J Pharm Biopharm 74, 427-434 DOI |
4 | Lesina E, Dames P and Rudolph C (2010) The effect of CpG motifs on gene expression and clearance kinetics of aerosol administered polyethylenimine (PEI)-plasmid DNA complexes in the lung. J Control Release 143, 243-250 DOI |
5 | Pringle IA, Hyde SC, Connolly MM et al (2012) CpG-free plasmid expression cassettes for cystic fibrosis gene therapy. Biomaterials 33, 6833-6842 DOI |
6 | Mann CJ, Anguela XM, Montane J et al (2012) Molecular signature of the immune and tissue response to non-coding plasmid DNA in skeletal muscle after electrotransfer. Gene Ther 19, 1177-1186 DOI |
7 | Yew NS, Zhao H, Przybylska M et al (2002) CpG-depleted plasmid DNA vectors with enhanced safety and long-term gene expression in vivo. Mol Ther 5, 731-738 DOI |
8 | Hodges BL, Taylor KM, Joseph MF, Bourgeois SA and Scheule RK (2004) Long-term transgene expression from plasmid DNA gene therapy vectors is negatively affected by CpG dinucleotides. Mol Ther 10, 269-278 DOI |
9 | Morrissey MA, Williamson AP, Steinbach AM et al (2018) Chimeric antigen receptors that trigger phagocytosis. eLife 7, e36688 DOI |
10 | Mosaad YM (2014) Hematopoietic stem cells: an overview. Transfus Apher Sci 51, 68-82 DOI |
11 | Piechaczek C, Fetzer C, Baiker A, Bode J and Lipps HJ (1999) A vector based on the SV40 origin of replication and chromosomal S/MARs replicates episomally in CHO cells. Nucleic Acids Res 27, 426-428 DOI |
12 | Ramezani A, Hawley TS and Hawley RG (2003) Performance- and safety-enhanced lentiviral vectors containing the human interferon-beta scaffold attachment region and the chicken beta-globin insulator. Blood 101, 4717-4724 DOI |
13 | Schubeler D, Mielke C, Maass K and Bode J (1996) Scaffold/matrix-attached regions act upon transcription in a context-dependent manner. Biochemistry 35, 11160-11169 DOI |
14 | Giannakopoulos A, Stavrou EF, Zarkadis I, Zoumbos N, Thrasher AJ and Athanassiadou A (2009) The functional role of S/MARs in episomal vectors as defined by the stressinduced destabilization profile of the vector sequences. J Mol Biol 387, 1239-1249 DOI |
15 | Stacey KJ, Ross IL and Hume DA (1993) Electroporation and DNA-dependent cell death in murine macrophages. Immunol Cell Biol 71 ( Pt 2), 75-85 DOI |
16 | Rupprecht AP and Coleman DL (1991) Transfection of adherent murine peritoneal macrophages with a reporter gene using DEAE-dextran. J Immunol Methods 144, 157-163 DOI |
17 | Kurdi AT, Glavey SV, Bezman NA et al (2018) Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab. Mol Cancer Ther 17, 1454-1463 DOI |
18 | Thompson CD, Frazier-Jessen MR, Rawat R, Nordan RP and Brown RT (1999) Evaluation of methods for transient transfection of a murine macrophage cell line, RAW 264.7. Biotechniques 27, 824-826, 828-830, 832 DOI |
19 | Shin DM, Yang CS, Yuk JM et al (2008) Mycobacterium abscessus activates the macrophage innate immune response via a physical and functional interaction between TLR2 and dectin-1. Cell Microbiol 10, 1608-1621 DOI |
20 | Shi Y, Fan X, Deng H et al (2015) Trastuzumab triggers phagocytic killing of high HER2 cancer cells in vitro and in vivo by interaction with Fcgamma receptors on macrophages. J Immunol 194, 4379-4386 DOI |
21 | Michaud HA, Eliaou JF, Lafont V, Bonnefoy N and Gros L (2014) Tumor antigen-targeting monoclonal antibody-based immunotherapy: Orchestrating combined strategies for the development of long-term antitumor immunity. Oncoimmunology 3, e955684 DOI |
22 | Lee S, Kivimae S, Dolor A and Szoka FC (2016) Macrophage-based cell therapies: The long and winding road. J Control Release 240, 527-540 DOI |
23 | Genard G, Lucas S and Michiels C (2017) Reprogramming of Tumor-Associated Macrophages with Anticancer Therapies: Radiotherapy versus Chemo- and Immunotherapies. Front Immunol 8, 828 DOI |
24 | Engelman A (2005) The ups and downs of gene expression and retroviral DNA integration. Proc Natl Acad Sci U S A 102, 1275-1276 DOI |
25 | Shayakhmetov DM, Gaggar A, Ni S, Li ZY and Lieber A (2005) Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. J Virol 79, 7478-7491 DOI |
26 | Zhang X, Edwards JP and Mosser DM (2009) The expression of exogenous genes in macrophages: obstacles and opportunities. Methods Mol Biol 531, 123-143 DOI |
27 | Overdijk MB, Verploegen S, Bogels M et al (2015) Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs 7, 311-321 DOI |
28 | Hardee CL, Arevalo-Soliz LM, Hornstein BD and Zechiedrich L (2017) Advances in Non-Viral DNA Vectors for Gene Therapy. Genes (Basel) 8, 65 DOI |
29 | Mun JY, Shin KK, Kwon O, Lim YT and Oh DB (2016) Minicircle microporation-based non-viral gene delivery improved the targeting of mesenchymal stem cells to an injury site. Biomaterials 101, 310-320 DOI |
30 | Leslie M (2018) New cancer-fighting cells enter trials. Science 361, 1056-1057 DOI |
31 | Chao MP, Alizadeh AA, Tang C et al (2010) Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 142, 699-713 DOI |